-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 20, 2021, Nanjing Yaoshi Technology Co.
, Ltd.
and Beijing First Pharmaceuticals Holdings (Beijing) Co.
, Ltd.
signed a type 1 innovative drug development and production cooperation agreement.
The two parties will develop the API for the second-generation ALK inhibitor CT-707 project Carry out in-depth strategic cooperation in production and NDA (New Drug Application, new drug marketing authorization application) registration and other related work, until it is approved by the State Drug Administration
.
CT-707 is a new generation of highly selective and highly active ALK/FAK/IGF1R multi-target kinase inhibitor independently developed by First Pharmaceutical Holdings and with complete intellectual property rights
.
In pre-clinical animal models, oral administration of CT-707 can not only eliminate tumors in animals, but also inhibit tumor metastasis in the lungs
Since 2014, Yaoshi Technology has maintained long-term and stable cooperation with First Pharmaceutical Holdings and its subsidiaries in innovative drug research and development, production services, etc.
The signing of the CT-707 project represents a milestone breakthrough in the comprehensive cooperation between the two parties
.
Yaoshi Technology will invest the most sufficient R&D and GMP production resources, and use the advantages of innovative technology to help Beijing Capital Group accelerate the advancement of the CT-707 project and the approval of the NDA registration
Li Wenjun, Chairman of First Pharmaceutical Holdings, said: "In the past years of cooperation, Yaoshi Technology has demonstrated excellent R&D and production delivery capabilities, helping us solve many bottlenecks in projects, and is a highly professional and trustworthy CMC partner
.
We hope to further accelerate the launch of CT-707 through cooperation with Yaksek Technology, and provide more innovative treatment options for patients with non-small cell lung cancer in China
Yang Minmin, Chairman of Medicine Stone Technology, said: “Shouyao Holdings is a dynamic and sentimental Chinese innovative drug research and development company.
We are very honored to be directly involved in the development and production of second-generation ALK inhibitor drugs
.
Medicine Stone Technology has accumulated over the past ten years.
